Vir Biotechnology, Inc.

This study is testing whether a two-drug combination (tobevibart + elebsiran) can help people with chronic hepatitis D infection who didn't get better with their current bulevirtide treatment. Researchers want to see if this new approach can reduce the hepatitis D virus in the bl…

This early-stage trial is testing a new drug called VIR-5818, both by itself and combined with an existing immunotherapy (pembrolizumab), in people with advanced HER2-positive cancers that have spread. The main goals are to find safe doses and see how the body processes the drug,…

This is the first human study testing an experimental drug called VIR-5500 for advanced prostate cancer that has stopped responding to standard treatments. Researchers will enroll 390 men to check if the drug is safe, how it moves through the body, and whether it shows early sign…

This is the first human study of a new experimental drug called VIR-5525 for people with advanced solid tumors that have spread or cannot be removed by surgery. Researchers will test VIR-5525 alone and combined with an existing immunotherapy drug (pembrolizumab) in 450 participan…